Fig. 6
From: Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression
HBV induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. HBV infection induces cIAP2 expression through PI3K/Akt/NF-κB signaling pathway. The upregulated cIAP2 promotes cell survival by reducing caspase-3 level. The cIAP2-enhanced cell survival renders the cells more resistant to sorafenib treatment, while anti-HBV treatment with lamivudine can suppress the upregulation of cIAP2 and consequently restore cancer cell sensitivity to sorafenib